Evidence map›Paper›PMID 41689709›Full record

ArticleMolecular and cellular biochemistry2026

MiRNA based liquid biopsy for castration-resistant prostate cancer diagnostics.

Maria Y Konoshenko, Milena M Saitkulova, Ekaterina V Shutko, Ilya A Ostaltsev, Pavel P Laktionov, Olga E Bryzgunova

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria Y KonoshenkoInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.
Milena M SaitkulovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.
Ekaterina V ShutkoInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia. katshutko@gmail.com.
Ilya A OstaltsevE.N. Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation, Novosibirsk, 630055, Russia.
Pavel P LaktionovInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.
Olga E BryzgunovaInstitute of Chemical Biology and Fundamental Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.

Funding

Russian state-funded project for ICBFM SB RAS 125012900932-4
6 · The paper itself

Abstract

Androgen deprivation therapy (ADT) is widely used for prostate cancer (PCa) treatment. However, this treatment is not curative, and PCa progresses despite ADT, becoming castration-resistant (CR). Castration-resistant prostate cancer (CRPCa) is a highly aggressive form of PCa that progresses, metastasizes, and develops treatment resistance rapidly. MiRNAs are known to be involved in cancer development mechanisms, including cell cycle regulation, apoptosis, angiogenesis, and epithelial-mesenchymal transition. The aim of the present work was a comparative analysis of the expression of 14 miRNAs involved in PCa development in hormone-sensitive prostate cancer (HSPCa) patients before any treatment, after ADT, in CRPCa, as well as in healthy donors (HD), to assess their diagnostic potential for CR. 44 differentially expressed miRNA ratios were found in urine extracellular vesicles (EVs), 41 in cell-free urine, and 35 in plasma EVs. ROC curve analysis was performed using three different control groups: HD + HSPCa, HSPCa, and HSPCa under maximal androgen blockade (MAB) treatment. For each biofluid and control group, the most diagnostically effective miRNA ratios were evaluated to identify minimal and redundant diagnostic panels. Urine EVs provided the most diagnostically efficient miRNA ratios and panels. For the HD + HSPCa control group, the minimal panel consisting of 3 miRNA ratios was able to diagnose 95% of CRPCa patients, while a partially redundant panel of 5 miRNA ratios diagnosed 90% of CRPCa patients at least twice. For the HSPCa control group, two minimal panels consisting of 2 miRNA ratios each were able to diagnose 100% of CRPCa patients, and a redundant panel of 6 different miRNA ratios also diagnosed 100% of CRPCa patients at least twice. For the MAB control group, a minimal panel of 3 miRNA ratios diagnosed 100% of CRPCa patients, and a partially redundant panel consisting of 4 different miRNA ratios diagnosed 95% of CRPCa patients.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticMicroRNAsProstatic Neoplasms, Castration-ResistantRNA, NeoplasmAgedAged, 80 and overExtracellular VesiclesHumansLiquid BiopsyMaleMiddle AgedBiomarkers, TumorMicroRNAsRNA, NeoplasmAndrogen deprivation therapyCastration-resistantExtracellular vesiclesLiquid biopsyMiRNAProstate cancerUrine

Identifiers

PMID41689709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.